Weihua Guo

发表

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer

Yate-Ching Yuan, L. Bosserman, J. S. Lee, 2022, Cancers.

Cerebrospinal Fluid Cell-Free DNA-Based Detection of High Level of Genomic Instability Is Associated With Poor Prognosis in NSCLC Patients With Leptomeningeal Metastases

F. Zhao, P. Xing, Junling Li, 2022, Frontiers in Oncology.

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer

J. Waisman, Jian Ye, J. S. Lee, 2021, Journal for ImmunoTherapy of Cancer.

Natural killer group 2D receptor and its ligands in cancer immune escape

Z. Zeng, Xiaoling Li, W. Xiong, 2019, Molecular Cancer.

Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.

C. Presant, J. S. Lee, P. Frankel, 2021, European journal of cancer.

PD-L1 and ICOSL discriminate human Secretory and Helper dendritic cells in cancer, allergy and autoimmunity

J. Klijanienko, O. Lantz, V. Soumelis, 2022, Nature Communications.

Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer

J. Waisman, J. Mortimer, Yinghui Huang, 2022, JCI insight.

A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.

S. Highlander, J. Waisman, J. S. Lee, 2020, The oncologist.

Socioeconomic status, mental health, and nutrition are the principal traits for low back pain phenotyping: Data from the osteoarthritis initiative

Zeyu Huang, John T. Martin, Weihua Guo, 2023, JOR spine.

Screening of Long Non-coding RNAs Biomarkers for the Diagnosis of Tuberculosis and Preliminary Construction of a Clinical Diagnosis Model

Xuejiao Hu, Li-juan Wu, Jiajia Song, 2022, Frontiers in Microbiology.

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer

J. Waisman, J. S. Lee, P. Frankel, 2023, Cancer Immunology, Immunotherapy.

Pembrolizumab plus vorinostat is highly active in Hodgkin lymphoma, including patients refractory to prior PD-1 blockade.

Lei Gao, L. Kwak, S. Rosen, 2023, Blood.

STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity

Weihua Guo, Jiayi Tan, Peter P. Lee, 2024, EBioMedicine.

PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer

D. Simons, Lei Wang, Weihua Guo, 2024, Cell reports. Medicine.